Also on the agenda for day one at the Academy of Managed Care Pharmacy (AMCP) 24th Annual Meeting in San Francisco was a satellite symposium that focused on analyzing and applying evidence to improve the cost/benefit and risk/benefit outcomes in multiple sclerosis. One of the overarching themes throughout the 5 presentations that comprised the program was medication adherence.
Also on the agenda for day one at the Academy of Managed Care Pharmacy (AMCP) 24th Annual Meeting in San Francisco was a satellite symposium that focused on analyzing and applying evidence to improve the cost/benefit and risk/benefit outcomes in multiple sclerosis (MS). One of the overarching themes throughout the 5 presentations that comprised the program was medication adherence.
There are many reasons why patient compliance and adherence can become problematic throughout the course of treatment for MS. Some of the reasons that presenters discussed included patients’ level of disability; curiosity about new modes of administration and other therapies; financial issues; injection fatigue; lack of support systems; and perceived lack of efficacy. And while lack of medication adherence leads to complications for patients being treated for all disease states, patients with MS in particular seem to have problems with adherence. In fact, 31% of patients with MS polled in a recent study have reported taking a deliberate break from treatment for one or more days. Even worse, 19% reported that they had stopped taking their MS treatment completely.
It is evident that patients with MS face many potential factors that could decrease their medication adherence. So what can be done? Healthcare providers can only do so much — changing therapies and encouraging patients to stick with a regimen does not work for all patients. The discussion in the session at one point turned to the potential of oral MS agents to improve adherence. The perception that they are better tolerated and the fact that this type of treatment is less invasive to daily activities could help patients adhere to the medication. However, the perception that this type of treatment is less effective must be considered as well.
Currently, MS treatments are long-term treatments that are often very costly and contain serious side effects. Considering that successful outcomes for patients require lifetime adherence and disease management, it is no surprise that many patients fail to adhere to their therapies at one time or another. However, there is hope that improving therapies by way of pharmacogenomics will not only improve therapies (and therefore the outlook of patients) but will also, in time, result in more affordable treatment. A recent genome-wide association study of 9722 cases from 15 countries identified 29 novel risk loci and multiple variants with roles in disease susceptibility. Researchers have also found that risk genes are often shared with other immunological disorders, such as type 1 diabetes and rheumatoid arthritis. As personalized medicine continues to help improve MS therapies, it should be expected that medication adherence rates for patients with MS will improve along with therapies.
For more infomation regarding the AMCP 24th Annual Meeting, please visit www.amcp.org.
Patient-Reported Outcomes Reinforce Efficacy of Natalizumab for MS
November 21st 2023Researchers gathered data on patient-reported outcomes to support evidence for the continuation of natalizumab, a disease-modifying treatment, in the management of multiple sclerosis (MS) progression.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Timing of Neurofilament Light Changes May Predict Multiple Sclerosis Worsening
November 16th 2023The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment
November 9th 2023Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.
Read More
Innovation in Value-Based Care Requires More Data, Patient-Centered Thinking
November 9th 2023In a panel discussion at the 2023 Patient-Centered Oncology Care® meeting held in Nashville, Tennessee, experts discussed the Enhancing Oncology Model and themes in the movement toward value-based care in oncology.
Read More